KCM
CORT icon

Kennedy Capital Management’s Corcept Therapeutics CORT Stock Holding History

Kennedy Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
304,615
+94,882
+45% +$3.55M 0.26% 141
2025
Q4 		$7.3M Buy
209,733
+79,807
+61% +$6.27M 0.15% 213
2025
Q3 		$10.8M Buy
129,926
+13,913
+12% +$1.01M 0.24% 145
2025
Q2 		$8.52M Buy
116,013
+30,090
+35% +$2.18M 0.2% 175
2025
Q1 		$9.81M Buy
85,923
+35,272
+70% +$2.15M 0.23% 149
2024
Q4 		$2.55M Sell
50,651
-249
-0.5% -$13K 0.06% 473
2024
Q3 		$2.36M Buy
+50,900
New +$1.81M 0.05% 484
2024
Q1 		– Sell
-44,929
Closed -$1.46M – 736
2023
Q4 		$1.46M Buy
+44,929
New +$1.23M 0.03% 539

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Kennedy Capital Management's CORT Position: Q1 2026 in Review

Kennedy Capital Management increased its Corcept Therapeutics (CORT) stake by 45% in Q1 2026, buying an estimated $3.55M and bringing the position to 304,615 shares worth $12.3M. The position accounts for 0.26% of the portfolio, ranked #141.

Kennedy Capital Management first reported a position in CORT in Q4 2023 and has held it in 8 quarters since. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Kennedy Capital Management held 304,615 shares of Corcept Therapeutics worth $12.3M as of Q1 2026.
  • Kennedy Capital Management bought 94,882 Corcept Therapeutics shares in Q1 2026, an estimated $3.55M.
  • Corcept Therapeutics made up 0.26% of Kennedy Capital Management's portfolio in Q1 2026, its #141 holding.
  • Kennedy Capital Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.